Alison Slaughter
Overview
Explore the profile of Alison Slaughter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
701
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kessl J, Kutluay S, Townsend D, Rebensburg S, Slaughter A, Larue R, et al.
Cell
. 2016 Aug;
166(5):1257-1268.e12.
PMID: 27565348
While an essential role of HIV-1 integrase (IN) for integration of viral cDNA into human chromosome is established, studies with IN mutants and allosteric IN inhibitors (ALLINIs) have suggested that...
2.
Feng L, Dharmarajan V, Serrao E, Hoyte A, Larue R, Slaughter A, et al.
ACS Chem Biol
. 2016 Feb;
11(5):1313-21.
PMID: 26910179
Allosteric HIV-1 integrase inhibitors (ALLINIs) have recently emerged as a promising class of antiretroviral agents and are currently in clinical trials. In infected cells, ALLINIs potently inhibit viral replication by...
3.
Feng L, Larue R, Slaughter A, Kessl J, Kvaratskhelia M
Curr Top Microbiol Immunol
. 2015 Mar;
389:93-119.
PMID: 25778682
Multimeric HIV-1 integrase (IN) plays an essential, multifunctional role in virus replication and serves as an important therapeutic target. Structural and biochemical studies have revealed the importance of the ordered...
4.
Slaughter A, Jurado K, Deng N, Feng L, Kessl J, Shkriabai N, et al.
Retrovirology
. 2014 Nov;
11:100.
PMID: 25421939
Background: Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are an important new class of anti-HIV-1 agents. ALLINIs bind at the IN catalytic core domain (CCD) dimer interface occupying the principal binding...
5.
Shkriabai N, Dharmarajan V, Slaughter A, Kessl J, Larue R, Feng L, et al.
J Biol Chem
. 2014 Aug;
289(38):26430-26440.
PMID: 25118283
Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are a promising class of antiretroviral agents for clinical development. Although ALLINIs promote aberrant IN multimerization and inhibit IN interaction with its cellular cofactor...
6.
Sharma A, Slaughter A, Jena N, Feng L, Kessl J, Fadel H, et al.
PLoS Pathog
. 2014 May;
10(5):e1004171.
PMID: 24874515
The quinoline-based allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are promising candidates for clinically useful antiviral agents. Studies using these compounds have highlighted the role of IN in both early and...
7.
Sharma A, Larue R, Plumb M, Malani N, Male F, Slaughter A, et al.
Proc Natl Acad Sci U S A
. 2013 Jul;
110(29):12036-41.
PMID: 23818621
The selection of chromosomal targets for retroviral integration varies markedly, tracking with the genus of the retrovirus, suggestive of targeting by binding to cellular factors. γ-Retroviral murine leukemia virus (MLV)...
8.
Feng L, Sharma A, Slaughter A, Jena N, Koh Y, Shkriabai N, et al.
J Biol Chem
. 2013 Apr;
288(22):15813-20.
PMID: 23615903
Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are a very promising new class of anti-HIV-1 agents that exhibit a multimodal mechanism of action by allosterically modulating IN multimerization and interfering with...
9.
Jurado K, Wang H, Slaughter A, Feng L, Kessl J, Koh Y, et al.
Proc Natl Acad Sci U S A
. 2013 Apr;
110(21):8690-5.
PMID: 23610442
Integration is essential for HIV-1 replication, and the viral integrase (IN) protein is an important therapeutic target. Allosteric IN inhibitors (ALLINIs) that engage the IN dimer interface at the binding...
10.
Kessl J, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, Feng L, et al.
J Biol Chem
. 2012 Mar;
287(20):16801-11.
PMID: 22437836
The multifunctional HIV-1 enzyme integrase interacts with viral DNA and its key cellular cofactor LEDGF to effectively integrate the reverse transcript into a host cell chromosome. These interactions are crucial...